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Assessment of tumor control probability 
for high-dose-rate interstitial brachytherapy 
implants
Than S. KEHWAR, Syed F. AKBER*
SUMMARY
AIM: The study was designed to propose a novel concept of biologically effective equivalent uniform 
dose to calculate tumor control probability for HDR implants.
MATERIALS AND METHODS: The expression of biologically effective equivalent uniform dose was de-
rived for non-uniform dose distribution in HDR implants using quality indices and voxel-based tumor 
control probability.
RESULTS: The results of this study show that high dose regions of the implant have higher tumor con-
trol probability. But these regions may also have a large number of normal cells and consequently may 
lead to severe normal tissue complications. If tumor coverage was not proper then the overall tumor 
control probability would be low and might result in tumor recurrence. Higher values of external vol-
ume index, dose non-uniformity ratio and overdose volume index were related to higher normal tissue 
complication rates outside and inside the implants.
CONCLUSION: The present concept may provide an alternative approach to calculate tumor control 
probability for HDR implants.
KEY WORDS: HDR interstitial implants, quality indices, non-optimization, geometric optimiza-
tion of volume, biologically effective equivalent uniform dose
BACKGROUND
In order to obtain optimal tumor cell kill-
ing with uniform clonogenic cell density and 
to avoid necrosis of the normal cell present 
within the target volume, the dose distribution 
within the target volume should be uniform 
[1, 2, 3]. However in high-dose-rate (HDR) 
interstitial implants it is diffi cult to achieve a 
uniform dose distribution because of the very 
high radiation dose in the vicinity of the ra-
diation source. Hence, the tumor control prob-
ability (TCP) calculated on the basis of mini-
mum or mean or median target dose would not 
be appropriate to predict accurate treatment 
outcome. To solve the problem, an imaginary 
ideal implant was divided into a large num-
ber of voxels to derive the biologically effec-
tive equivalent uniform dose (BEEUD) using 
voxel-based TCP. Then the HDR implant was 
divided into four different regions, based on 
the pattern of dose distribution, to defi ne qual-
ity indices (QI). The BEEUD and QIs were 
introduced into the equation of TCP to get an 
expression for HDR implants. 
AIM
The aim of the study was to design the TCP 
concept for HDR implants, by introducing a 
hypothetical dose, BEEUD. 
MATERIALS AND METHODS
To account for non-uniform dose distribution 
of the HDR interstitial implant, the target vol-
ume is divided into n sub-volumes (voxels), 
and it is assumed that the dose distribution 
within each individual voxel is uniform. The 
TCP is calculated voxel by voxel. The TCPs 
of these voxels are mutually exclusive; hence 
the net TCP for the entire target volume can 
be written as
TCP = Π exp[–ρ vi exp(–αBEDi)]        (1)
where Π, ρ, and BEDi are the clonogenic cell 
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density, coeffi cient of lethal damage (radio-
sensitivity of lethal damage) for the target 
cells, and the biologically effective dose of the 
ith voxel of volume vi of the target volume, re-
spectively. Here i = 1, 2, 3, .........n.  Equation 
(1) may also be written as 
TCP = exp[–ρΣvi exp(–αBEDi)]               (2)  
The BEEUD is a hypothetical biological 
dose that produces an equivalent biological ef-
fect to that of an absolutely uniform dose de-
livered to the entire target volume V. For such 
type of dose the TCP may be given by
TCP =  exp[–ρV exp(–αBEEUD)]          (3)
From equations (2) and (3), it may be writ-
ten as
BEEUD = –(1/α) ln[(1/V)Σvi exp(–αBEDi)] 
or 
BEEUD = ln[(1/V)Σvi exp(–αBEDi)]–(1/α)     (4)
where i = 1, 2, 3, .........n.   To calculate TCP 
for a non-uniform dose distribution within the 
tumor, the use of BEEUD would be an appro-
priate term instead of BED. 
Region based TCP of tumor volume for an 
HDR implant
The different regions of the HDR implant are 
shown in Fig. 1, where the target volume is di-
vided into four regions: (1) the region which 
receives a dose less than the reference dose, 
(2) the region which receives a dose in the 
range of 1.0 to 1.5 times the reference dose, (3) 
the region which receives a dose in the range 
of 1.5 to 2.0 times the reference dose, and (4) 
the region which receives a dose equal to or 
more than 2.0 times the reference dose. 
With the use of BEEUD of each tumor re-
gion (Fig. 1) the expressions of TCP for each 
region is given as follows:
1. The TCP for the region of target volume 
which receives a dose less than the reference 
dose
TCP1 = exp[–ρ(TV–TVDref)exp(–αBEEUD1)]
or 
TCP1 = exp[–ρTVDref{(1–CI)/CI}exp(–αBEEUD1)]  (5)
where CI is the coverage index [4] and is de-
fi ned by TVDref/TV.
2. The TCP for the region of target volume 
that receives a dose in the range of 1.0 to 1.5 
times the reference dose
TCP2 = exp[–ρ(TVDref–TV1.5Dref)exp(–αBEEUD2)]
or 
TCP2 = exp[–ρTVDref.DHI exp(–αBEEUD2)]  (6)
where DHI is the relative dose homogeneity 
index [4] and is defi ned by (TVDref–TV1.5Dref)/
TVDref.
3. The TCP for the region of target volume 
that receives a dose in the range of 1.5 to 2.0 
times the reference dose
TCP3 = exp[–ρ(TV1.5Dref–TV2Dref)exp(–αBEEUD3)]
or 
TCP3 = exp[–ρTVDref(DNR–ODI)exp(–α BEEUD3)]  (7)
where DNR and ODI are the dose non-unifor-
mity ratio [5] and overdose volume index [4], 
and are defi ned by DNR = TV1.5Dref /TVDref and 
ODI = TV2.0Dref /TVDref, respectively.
4. The TCP for the region of target volume 
that receives a dose equal to or greater than 2 
times the reference dose
TCP4 = exp[–ρTV2Dref exp(–αBEEUD4)]
or 
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Fig. 1. Schematic diagram showing target volume (TV), portion 
of target volume (TVDref) that receives dose equal to or more than 
the reference dose Dref, the isodose surface that receives 1.5 times 
the reference dose (1.5 Dref), and that receives 2.0 times the refer-
ence dose (2.0 Dref).
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Quality Index Patient # 1 Patient # 2 Patient # 3 Patient # 4 Patient # 5
EI 0.120 0.159 0.093 0.121 0.120
CI 0.744 0.688 0.657 0.678 0.806
DHI 0.934 0.939 0.936 0.933 0.924
ODI 0.023 0.023 0.023 0.030 0.040
DNR 0.066 0.042 0.064 0.067 0.113
BEEUD1 36.129 31.034 28.568 36.240 38.693
BEEUD2 51.370 51.370 51.370 51.370 51.370
BEEUD3 83.905 83.905 83.905 83.905 83.905
BEEUD4 119.936 119.926 119.933 119.894 119.934
TCP1 0.902 0.494 0.100 0.939 0.987
TCP2 0.998 0.998 0.998 0.999 0.999
TCP3 1.000 1.000 1.000 1.000 1.000
TCP4 1.000 1.000 1.000 1.000 1.000
TCPnet 0.900 0.493 0.100 .0938 0.986
Table 1. Calculated values of QI, BEEUD and TCP for HDR implants [7].
TCP4 = exp[–ρTVDref.ODI exp(–αBEEUD4)] 
(8)
Now multiplying and rearranging equa-
tions (5) – (8), the expression of net TCP may 
be given by
TCP = exp[–ρTVDref{[(1-CI)/CI] exp(–αBEEUD1) 
+ DHI exp(–αBEEUD2) + (DNR–ODI) exp
(–αBEEUD3) + ODI exp(–αBEEUD4)}]        (9)
In equation (9) the effect of proliferation 
(Tp) has been neglected, and clonogenic cell 
density (ρ) and radio-sensitivity (α) were 
assumed to be constant throughout the target 
volume. 
Using the TCP expression derived for HDR 
implants, the published data of HDR implants 
were used to assess the applicability of the 
concept.
RESULTS
Using the BEEUD relation and to calculate 
TCP, the values of α/β = 10 Gy, α = 0.35 Gy-1 
[6], and clonogenic cell density ρ = 1000 per 
cc for lumpectomy breast cases were used. 
In Table 1 of Vicini et al. [7] the volumetric 
data for target volume are given for the total 
target volume, the minimum dose received 
by ≥90% of the target volume, the target vol-
umes receiving 100% and 150% of the pre-
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scribed dose (PD) of 32 Gy. The prescribed 
dose was 8 fractions of 4 Gy each given twice 
per day over 4 days. In the present calcula-
tions it is assumed that the minimum dose 
to the target volume is less than 5% of that 
received by ≥90% of the target volume, and 
in each case the maximum dose received by 
1.0 cc of the target volume is 70 Gy. The total 
breast volume was defi ned including target 
volume. The breast volume receiving 100% of 
the prescribed dose includes the target vol-
ume receiving 100% of the target volume. To 
fi nd out different values of the dose volumes 
of the normal breast tissue and target volume 
the method of linear interpolation is used. 
The QIs (CI, DHI, ODI and DNR), BEEUD 
and TCP of different portions of the tumor 
and normal breast tissue were calculated for 
these 5 patients and are listed in Table 1. 
DISCUSSION
Analytical expression for TCP incorporating 
QIs are derived in this work. The calculations 
of TCP done by other investigators [8, 9] were 
based on either the entire target volume with 
a single dose or by dividing the entire volume 
into small voxels. In this work, we have used 
a different approach. The TV is divided into 
4 regions to defi ne different QIs. The expres-
sions of BEEUD were derived for all regions 
Księga1.indb   76 2008-08-05   11:37:18
of TV, and were incorporated into the expres-
sion of the TCP.    
CONCLUSION
From Table 1, it appears that the high dose 
regions in the implant have higher values of 
TCP, which would contribute to higher tumor 
control, but at the same time these regions 
may also have a large number of normal cells, 
which consequently may lead to severe normal 
tissue complications, such as tissue necrosis. 
On the other hand, if the tumor coverage is not 
proper then the overall TCP would be low and 
might result in tumor recurrence. The higher 
values of EI in Table 1 are related to higher 
normal tissue complication rates too.
The present concept may provide an al-
ternative approach to estimate the TCP and 
would be an appropriate method to estimate 
the TCP in clinical settings and achieve better 
outcome of radiation treatment. 
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